With these tools, TSPO PET with [18F]GE-180 may enable straightforward clinical assessment of neuroinflammatory activity in MS beyond the scope of structural MRI and seems to be a highly promising imaging method to assess disease activity and therapy response in RRMS patients. The gene discussed is TSPO; the disease is relapsing-remitting multiple sclerosis.